Antibody Clinical Trials Manufacturing 
BioPharma Reporter
JULY 20, 2021
Kineta says the partnership with Samsung Biologics will help it advance its novel anti-VISTA antibody as it aims to start clinical trials next year.
XTalks
NOVEMBER 21, 2024
The test, the first of its kind approved for over-the-counter (OTC) use in the US, detects antibodies for Treponema pallidum , the bacterium responsible for syphilis. Using a single drop of blood, it delivers highly accurate results, with clinical trials showing a 99.5 percent accuracy rate for negative cases and 93.4
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 22, 2022
The iPSC-based allogeneic cell therapy platform of Umoja leverages its synthetic receptor enabled differentiation (ShRED) manufacturing process to guide iCIL differentiation and development with robust anti-tumour activity. In the initial stage, the partnership will focus on acute myeloid leukaemia (AML) to boost accessibility to patients.
Pharmaceutical Technology
NOVEMBER 14, 2022
In a field dominated by antibodies and small molecules, two cell-therapy based approaches have come under the spotlight for showing early signs of efficacy in treating lupus. Apart from the monoclonal antibodies and small molecules, researchers have long held an interest in exploring cell therapies for autoimmune conditions.
pharmaphorum
SEPTEMBER 4, 2020
Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. They said the trials would involve 440 adults at 11 sites across the US. They are also scaling up manufacturing of the antigen and adjuvant, aiming to produce up to a billion doses in 2021.
Pharmaceutical Technology
AUGUST 15, 2022
The latest MHRA decision is based on findings from the Phase II/III clinical trial, where the mRNA-1273.214 vaccine met all primary endpoints. In baseline seronegative subjects, the updated vaccine offered a superior neutralising antibody response against Omicron (BA.1) 1) versus the 50µg mRNA-1273 booster dose.
STAT News
JANUARY 10, 2023
SAN FRANCISCO — For months, drugmakers have been pleading with regulators to lower the bar for authorizing antibody drugs for Covid. The virus, they noted, had evolved fast enough to render every previous antibody obsolete.
Expert insights. Personalized for you.
98 
Let's personalize your content